Strategies for targeting tumour necrosis factor in IBD

Bailliere's Best Practice and Research in Clinical Gastroenterology

Volumn 17, Issue 1, 2003, Pages 105-117

  Sandborn, William J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Adalimumab; CDP571; CDP870; CNI 1493; Crohn's disease; Etanercept; Infliximab; Onercept; Thalidomide; Tumour necrosis factor; Ulcerative colitis

Indexed keywords

ADALIMUMAB; ANTIIDIOTYPIC ANTIBODY; CERTOLIZUMAB PEGOL; ETANERCEPT; IMMUNOGLOBULIN F(AB) FRAGMENT; INFLIXIMAB; MACROGOL; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MONOCLONAL ANTIBODY; ONERCEPT; PLACEBO; PROTEIN P55; SEMAPIMOD; STEROID; THALIDOMIDE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; IMMUNOSUPPRESSIVE AGENT; TUMOR NECROSIS FACTOR ALPHA; AZATHIOPRINE; CHIMERIC ANTIBODY; MERCAPTOPURINE; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE;

ANKYLOSING SPONDYLITIS; ANTIBODY PRODUCTION; ARTICLE; CLINICAL TRIAL; COLON FISTULA; CONSTIPATION; CROHN DISEASE; DELAYED HYPERSENSITIVITY; DRUG CONJUGATION; DRUG EFFICACY; DRUG TARGETING; ENTERITIS; HUMAN; IMMUNOPATHOLOGY; LUPUS VULGARIS; NONHODGKIN LYMPHOMA; PERIPHERAL NEUROPATHY; PROTEIN FUNCTION; RASH; REMISSION; SEBORRHEA; SIDE EFFECT; TERATOGENICITY; TUBERCULOSIS; ULCERATIVE COLITIS; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; IMMUNOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME; ANUS FISTULA; ARTHRALGIA; ASPERGILLOSIS; DRUG INDUCED DISEASE; DRUG SAFETY; DYSPHAGIA; DYSPNEA; FACE EDEMA; FEVER; HAND DISEASE; HEADACHE; HISTOPLASMOSIS; HYPOTENSION; LIP DISEASE; LISTERIOSIS; MYALGIA; PRURITUS; RHEUMATOID ARTHRITIS; SEPSIS; SINGLE DRUG DOSE; SORE THROAT; URTICARIA;

ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037630208     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1053/bega.2002.0345     Document Type: Article

References (46)

1. MacDonald, T T, Monteleone, G, & Pender, S L (2000). Recent developments in the immunology of inflammatory bowel disease. Scandinavian Journal of Immunology, 51 2-9.
2. Papadakis, K A, & Targan, S R (2000). Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology, 119 1148-1157.
3. Murch, S H, Lamkin, V A, & Savage, M O et al. (1991). Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut, 32 913-917.
4. Braegger, C P, Nicholls, S, & Murch, S H et al. (1992). Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet, 339 89-91.
5. Murch, S H, Braegger, C P, Walker-Smith, J A, & MacDonald, T T et al. (1993). Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut, 34 1705-1709.
6. Targan, S R, Hanauer, S B, & van Deventer, S J et al. (1997). A short-term study of chimeric monoclonal antibody cA2 to tumour necrosis factor alpha for Crohn's disease. New England Journal of Medicine, 337 1029-1035.
7. Present, D H, Rutgeerts, P, & Targan, S et al. (1993). Infliximab for the treatment of fistulas in patients with Crohn's disease. New England Journal of Medicine, 340 1398-1405.
8. Hanauer, S B, Feagan, B G, & Lichtenstein, G R et al. (2002). Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet, 359 1541-1549.
9. Stack, W A, Mann, S D, & Roy, A J et al. (1997). Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet, 349 521-524.
10. Sandborn, W J, Feagan, B G, & Hanauer, S B et al. (2001). An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology, 120 1330-1338.
11. Feagan, B G, Sandborn, W J, & Baker, J et al. (2000). A randomized, double-blind, placebo-controlled, multi-center trial of the engineered human antibody to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn's disease. Gastroenterology, 118 A655.
12. Sandborn, W J, & Targan, S R (2002). Biologic therapy of inflammatory bowel disease. Gastroenterology, 122 1592-1608.
13. Sandborn, W J, & Hanauer, S B (1999). Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflammatory Bowel Disease, 5 119-133.
14. Scallon, B J, Moore, M A, & Trinh, H et al. (1995). Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine, 7 251-259.
15. Lugering, A, Schmidt, M, & Lugering, N et al. (2001). Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology, 121 1145-1157.
16. ten Hove, T, van Montfrans, C, Peppelenbosch, M P, & van Deventer, S J (2002). Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut, 50 206-211.
17. Lee, J C, Kumar, S, & Griswold, D E et al. (2000). Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology, 47 185-201.
18. Salituro, F G, Germann, U A, & Wilson, K P et al. (1999). Inhibitors of p38 MAP kinase: therapeutic intervention in cytokine-mediated diseases. Current Medicinal Chemistry, 6 807-823.
19. van Deventer, S J (2001). Transmembrane TNF-alpha, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease. Gastroenterology, 121 1242-1246.
20. Rutgeerts, P, D'Haens, G, & Targan, S et al. (1999). Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology, 117 761-769.
21. Sands, B, Van Deventer, S, & Bernstein, C et al. (2002). Long-term treatment of fistulizing Crohn's disease: response to infliximab in the ACCENT II trial through 54 weeks. Gastroenterology, 122 A81.
22. Sands, B E, Tremaine, W J, & Sandborn, W J et al. (2001). Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflammatory Bowel Disease, 7 83-88.
23. Probert, S JL, Hearing, S D, & Schreiber, S et al. (2002). Infliximab in steroid-resistant ulcerative colitis: a randomized controlled trial. Gastroenterology, 122 A99.
24. Chey, W Y, Hussain, A, & Ryan, C et al. (2001). Infliximab for refractory ulcerative colitis. American Journal of Gastroenterology, 96 2373-2381.
25. Braun, J, Brandt, J, & Listing, J et al. (2002). Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet, 359 1187-1193.
26. Schaible, T F (2000). Long term safety of infliximab. Canadian Journal of Gastroenterology, 14 (supplement C): 29C-32C.
27. Norman, M, Baert, F, & D'Haens, G et al. (2001). HACA formation after infliximab (Remicade) treatment in Crohn's disease is clearly associated with infusion reactions. Gastroenterology, 120 A261.
28. Farrell, R, Alsahli, M, & Falchuk, K et al. (2001). Human anti-chimeric antibody levels correlate with lack of response and infusion reactions following infliximab therapy. Gastroenterology, 120 A-69.
29. Farrell, R, Alsahli, M, & Falchuk, K et al. (2001). A randomized, double-blind, placebo-controlled trial of intravenous hydrocortisone in reducing human anti-chimeric antibody following infliximab therapy. Gastroenterology, 120 A618-A619.
30. Hanauer, S, Rutgeerts, P, & Targan, S et al. (1999). Delayed hypersensitivity to infliximab (Remicade) re-infusion after a 2-4 year interval without treatment. Gastroenterology, 116 A731.
31. Hanauer, S, Schreiber, S, & Bao, W et al. (2001). ACCENT I trial: infliximab response rates over 30 weeks. American Journal of Gastroentrology, 96 S302.
32. Ricart, E, Panaccione, R, & Loftus, E V et al. (2001). Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. American Journal of Gastroenterology, 96 722-729.
33. Vermeire, S, Norman, M, & Van Assche, G et al. (2001). Infliximab (Remicade) treatment in Crohn's disease and antinuclear antibody (ANA) formation. Gastroenterology, 120 A-96.
34. Bickston, S J, Lichtenstein, G R, & Arseneau, K O et al. (1999). The relationship between infliximab treatment and lymphoma in Crohn's disease. Gastroenterology, 117 1433-1437.
35. Sachmechian, A, Vasiliauskas, E, & Abreu, M et al. (2001). Malignancy following Remicade therapy: incidence and characteristics. Gastroenterology, 120 A-619.
36. Keane, J, Gershon, S, & Wise, R P et al. (2001). Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. New England Journal of Medicine, 345 1098-1104.
37. Warris, A, Bjorneklett, A, & Gaustad, P (2001). Invasive pulmonary aspergillosis associated with infliximab therapy. New England Journal of Medicine, 344 1099-1100.
38. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of ATS Board of Directors, July 1999. This statements was endorsed by the Council of the Infectious Disease Society of America, September 1999. American Journal of Respiratory and Critical Care Medicine 2000; 161: 1376-1395.
39. Evans, R C, Clarke, L, & Heath, P et al. (1997). Treatment of ulcerative colitis with an engineered human anti-TNFalpha antibody CDP571. Alimentary Pharmacology and Therapeutics, 11 1031-1035.
40. D'Haens, G, Swijsen, C, & Noman, M et al. (2001). Etanercept in the treatment of active refractory Crohn's disease: a single-center pilot trial. American Journal of Gastroenterology, 96 2564-2568.
41. Sandborn, W J, Hanauer, SB, & Katz, S et al. (2001). Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology, 121 1088-1094.
42. Gorman, J D, Sack, K E, & Davis, Jr. J C (2002). Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. New England Journal of Medicine, 346 1349-1356.
43. Rutgeerts, P, Lemmens, L, & Van Assche, G et al. (2001). Recombinant soluble p55 receptor induces remission, is non-immunogenic and well tolerated in active Crohn's disease: results of a randomized pilot trial. Gastroenterology, 120 A452.
44. Vasiliauskas, E A, Kam, L Y, & Abreu-Martin, M T et al. (1999). An open-label pilot study of low-dose thalidomide in chronically active, sterioid-dependent Crohn's disease. Gastroenterology, 117 1278-1287.
45. Ehrenpreis, E D, Kane, S V, & Cohen, L B et al. (1999). Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology, 117 1271-1277.
46. Hommes, D, Van Den Blink, B, & Plasse, T et al. (2002). Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology, 122 7-14.